{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:20:14Z","timestamp":1762867214210},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T00:00:00Z","timestamp":1507593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Oral immunosuppressive drugs are frequently prescribed in young women with atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>). Immunocompromised patients may have a higher risk of developing high\u2010risk <jats:styled-content style=\"fixed-case\">HPV<\/jats:styled-content> infections, cervical intra\u2010epithelial neoplasia (<jats:styled-content style=\"fixed-case\">CIN<\/jats:styled-content>) and cervical carcinoma. Most literature on patients using oral immunosuppressive drugs is available in organ transplant patients. Literature on the risk of developing cervical carcinoma in <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients treated with oral immunosuppressive drugs is lacking. At this moment, there is no clear guideline\/consensus on this topic, but in daily practice, questions arise concerning whether this risk is increased and whether more intensive screening in women using immunosuppressive drugs should take place.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the occurrence of cervical carcinoma in women with <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> treated with oral immunosuppressive drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective cohort study in two university medical centres in the Netherlands, all female adult <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients receiving oral immunosuppressive drugs (cyclosporine A, azathioprine, methotrexate, mycophenolate mofetil, enteric\u2010coated mycophenolate sodium and extended release tacrolimus) for more than 2 months between 1989 and 1 January 2014 were included. Patient files in the national histopathology register were screened for <jats:styled-content style=\"fixed-case\">PAP<\/jats:styled-content>3a, <jats:styled-content style=\"fixed-case\">CIN<\/jats:styled-content> I, <jats:styled-content style=\"fixed-case\">CIN II<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> CIN III<\/jats:styled-content> and cervical carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 257 female <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> patients with one or more treatment episodes from 1989 until 1 January 2014 were identified and included in this study. In 189 patients (73.5%), results of cervical examination were reported in the national histopathology database. Median total duration of treatment in these 189 women was 407.0 days (IQR 243.0\u2013940.0). No cervical carcinoma during or following immunosuppressive therapy was found in our patient group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>No intensified screening programme for cervical neoplasia seems necessary for women with <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> using oral immunosuppressive drugs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.14593","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T10:12:41Z","timestamp":1505815961000},"page":"271-275","source":"Crossref","is-referenced-by-count":6,"title":["Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?"],"prefix":"10.1111","volume":"32","author":[{"given":"F.M.","family":"Garritsen","sequence":"first","affiliation":[{"name":"Department of Dermatology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.H.M.","family":"Verheijen","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.G.","family":"Gerestein","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"van Zuilen","sequence":"additional","affiliation":[{"name":"Department of Nefrology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.F.","family":"Oosterhaven","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van Dijk","sequence":"additional","affiliation":[{"name":"Department of Pathology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.F.","family":"Bruijnzeel\u2010Koomen","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"de Bruin\u2010Weller","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,10,10]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24439"},{"key":"e_1_2_6_3_1","first-page":"741","article-title":"Infectious complications after liver transplantation","volume":"11","author":"Hernandez Mdel P","year":"2015","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1866"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000357907"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027621"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-9-117"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.02.008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61050-2"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.011841"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13609"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.23.2823"},{"key":"e_1_2_6_13_1","first-page":"359","article-title":"Gynecologic malignancies in immunosuppressed organ homograft recipients","volume":"45","author":"Porreco R","year":"1975","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.884029"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12472"},{"key":"e_1_2_6_16_1","unstructured":"van derVeenVN CarpayMEM vanDeldenJA et al.Uitvoeringstoets wijziging bevolkingsonderzoek baarmoederhalskanker2013. URLhttp:\/\/www.rivm.nl\/Documenten_en_publicaties\/Wetenschappelijk\/Rapporten\/2013\/oktober\/Uitvoeringstoets_wijziging_bevolkingsonderzoek_baarmoederhalskanker_2013(last accessed: 05 July 2017)."},{"key":"e_1_2_6_17_1","volume-title":"De praktijk van het bevolkingsondezoek naar baarmoederhals kanker in Nederland in 2001","author":"Ballegooijen M","year":"2003"},{"key":"e_1_2_6_18_1","unstructured":"Dutch National Guideline CIN AIS en VAIN2015. URLhttp:\/\/www.oncoline.nl\/cin-ais-en-vain(last accessed: 5 July 2017)."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000447425.03351.8b"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14593","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T03:37:17Z","timestamp":1695008237000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,10]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/jdv.14593"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14593","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,10]]}}}